SOM Shares SomnoMed Limited
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Sleep-health device leadership and recurring international demand provide scalable growth with catalyst potential.
Future value: $0.84 (+193.57%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Recurring device demand and growth-story catalyst profile
- ▾Below 50-day MA (-9.35%)
- ▸Volume 2.44× average — accumulation
- ▾Near 52-week low (7.7% of range)
- ▸~194% upside to price target
Is SOM a buy right now?
Trend: SOM is trading below the 50-day average (-6.45%), RSI 55 — neutral momentum, with a 3-month return of -38.30%.
Valuation & quality: SomnoMed Limited trades on forward P/E 12.2, PEG 0.99, price-to-book 1.34; fundamentals show net margin -2.3%, return on equity -5.7%, revenue growth -6.9% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$0.84 (+188.5% vs the last close; range A$0.76 – A$0.99), consensus rating “none”.
Our screen: BUY (score 3) — Sleep-health device leadership and recurring international demand provide scalable growth with catalyst potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -15.10% | -9.70% | +1.80% | -8.80% | -13.50% | -24.40% | -14.70% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About SomnoMed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe.
Sector: Healthcare · Industry: Medical Devices · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.